NCT07056595View on ClinicalTrials.gov

Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 21, 2025

Primary Completion Date

May 21, 2026

Study Completion Date

May 21, 2026

Conditions
IgA Nephropathy (IgAN)
Interventions
DRUG

Finerenone

Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist. Planned dose - 10 mg/day

Trial Locations (1)

Unknown

RECRUITING

Botkin Hospital, Moscow

All Listed Sponsors
lead

Botkin Hospital

OTHER